

**PROGRAM SCHEDULE**  
*The 2022 Annual Retreat on Cancer Research in New Jersey*  
*May 25, 2022*

*College Avenue Student Center, Rutgers University*  
*126 College Avenue, New Brunswick*

<b>8:00 - 9:30 A.M.</b>	<b>Breakfast and Registration (Main Lounge)</b>
<b>8:30 - 9:30 A.M.</b>	<b>Posters Set Up (Main Lounge)</b>
<b>9:30 A.M. - 4:30 P.M.</b>	<b>Poster Session (Main Lounge)</b>
<b>9:30 - 11:00 A.M.</b>	<b>All Authors Present</b>
<b>11:00 - 11:05 A.M.</b>	<b>Welcome and Introduction (Multi-Purpose Room A&amp;B)</b>

**Steven K. Libutti, MD, FACS**  
**Director**  
**Rutgers Cancer Institute of New Jersey**

<b>11:05 A.M. - 12:00 P.M.</b>	<b>Keynote Address (Multi-Purpose Room A&amp;B)</b>
--------------------------------	---

***“Stem Cells: Coping with Stress and Memories”***

**Elaine Fuchs, Ph.D.**

Rebecca C. Lancefield Professor of  
Mammalian Cell Biology and Development  
Rockefeller University

<b>12:00 - 1:00 P.M.</b>	<b>Lunch (Food Court)</b>
<b>1:00 - 4:00 P.M.</b>	<b>Focus Session A (Multi-Purpose Room A)</b>
	<b>1:00 – 2:00 P.M. Cancer Metabolism and Immunology</b>
	<b>2:00 - 3:00 P.M. Genome Instability and Cancer Genetics</b>
	<b>3:00 - 4:00 P.M. Cancer Pharmacology</b>
<b>1:00 - 3:00 P.M.</b>	<b>Focus Session B (Multi-Purpose Room B)</b>
	<b>1:00 – 2:00 P.M. Clinical Investigations and Precision Therapeutics</b>
	<b>2:00 - 3:00 P.M. Cancer Prevention and Control</b>
<b>3:00 - 4:30 P.M.</b>	<b>Clinical Trials in Progress Poster Session –Authors Present (Main Lounge)</b>
<b>4:30 P.M.</b>	<b>End of Program</b>

# PROGRAM SCHEDULE

## Focus Session A – Multi-Purpose Room A

### Cancer Metabolism and Immunology

1:00 P.M. – 2:00 P.M.

**Co-Chairs:** **Yanxiang (Jessie) Guo, PhD**, Associate Professor of Medicine, Rutgers Robert Wood Johnson Medical School, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ  
**Danelle Davenport, MSc, PhD**, Associate Professor of Molecular Biology, Princeton University, Princeton, NJ

#### **(A1) IDENTIFICATION OF ZBTB24 AS A NOVEL TUMOR SUPPRESSOR IN HEMATOLOGICAL MALIGNANCIES**

Rongrong Li<sup>1</sup>, Namratha Sheshadri<sup>1</sup>, Jianliang Shen<sup>1</sup>, Kevin Lu<sup>2</sup>, Zhiyuan Shen<sup>2</sup>, Wei-Xing Zong<sup>1,2</sup>

<sup>1</sup>Department of Chemical Biology, Ernest Mario School of Pharmacy, Piscataway, NJ

<sup>2</sup>Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

#### **(A2) CYCLIN C SUPPRESSES PANCREATIC INTERDUCTAL NEOPLASIA AND NEUROENDOCRINE NEOPLASIA PROGRESSION IN A MURINE KRAS MODEL**

Kathy Qi Cai<sup>1</sup>, Sara Hanley<sup>2</sup>, David C. Stieg<sup>2</sup>, Andre-Klein Santos<sup>1</sup>, Kerry S. Campbell<sup>1</sup>, Randy Strich<sup>2</sup>

<sup>1</sup>Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, PA

<sup>2</sup>Department of Molecular Biology, Graduate School of Biological Sciences, Rowan University School of Osteopathic Medicine, Stratford, NJ

#### **(A3) SOX9 PROMOTES TUMORIGENESIS IN THE KRAS<sup>G12D</sup> LUNG CANCER MOUSE MODEL THROUGH INCREASING CANCER CELL PROLIFERATION AND SUPPRESSING T CELL FUNCTION**

Hua Zhong, Gregory Riedlinger, Jessie Yanxiang Guo, Hatem Sabaawy, Sharon Pine

Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

#### **(A4) ARGININE METABOLISM CONFERS METABOLIC VULNERABILITY IN PDAC**

Junrong Yan<sup>1</sup>, Sara Maimouni<sup>1,2</sup>, Heineken Queen Daguplo<sup>1</sup>, Jianliang Shen<sup>1</sup>, Eric Chiles<sup>2</sup>, Luke Torre-Healy<sup>3</sup>, Yun Jae Yoo<sup>3</sup>, Xiaoxuan Lu<sup>1</sup>, Costas Lyssiotis<sup>4</sup>, He Wang<sup>5</sup>, Richard Moffitt<sup>3</sup>, Xiaoyang Su<sup>2</sup>, Wei-Xing Zong<sup>1,2</sup>

<sup>1</sup>Department of Chemical Biology, Ernest Mario School of Pharmacy, Piscataway, NJ

<sup>2</sup>Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

<sup>3</sup>Department of Biomedical Informatics, Stony Brook University, Stony Brook, NY

<sup>4</sup>Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI

<sup>5</sup>Department of Pathology and Laboratory Medicine, Rutgers Robert Wood Johnson Medical School, Piscataway, NJ

#### **(A5) CPT1A-MEDIATED REGULATION OF ENDOCRINE THERAPY RESISTANCE IN ER+ BREAST CANCER**

Shaimaa Hussein<sup>1,2</sup>, Michael L. Gatzka<sup>1,2</sup>, and Shridar Ganesan<sup>1,3</sup>

<sup>1</sup>Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

<sup>2</sup>Department of Radiation Oncology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ

<sup>3</sup>Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ

# PROGRAM SCHEDULE

## Focus Session A – Multi-Purpose Room A

### *Genomic Instability and Cancer Genetics*

**2:00 P.M. – 3:00 P.M.**

**Co-Chairs:** **Wenwei Hu, PhD**, Professor of Radiation Oncology, Rutgers Robert Wood Johnson Medical School, Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ  
**Benjamin Raphael, PhD**, Professor, Department of Computer Science, Princeton University, Princeton NJ

#### **(A6) DELINEATING DYNAMIC CELL STATE HETEROGENEITY IN BLADDER CANCER**

Antara Biswas, Subhajyoti De  
Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

#### **(A7) EPIGENETIC REGULATION OF BREAST CANCER DORMANCY**

Alejandra I. Ferrer<sup>1,2</sup>, Garima Sinha<sup>1,2</sup>, Oleta Sandiford<sup>1</sup>, Pranela Rameshwar<sup>2</sup>  
<sup>1</sup>School of Graduate Studies, Rutgers, The State University of New Jersey, Newark, NJ  
<sup>2</sup>Department of Medicine, Rutgers, The State University of New Jersey, Newark, NJ

#### **(A8) REGULATION OF THE G2/M CELL CYCLE CHECKPOINT BY BRCA1**

Yanira González-Rodríguez<sup>1</sup>, Samuel F. Bunting<sup>2</sup>  
<sup>1</sup>Graduate PhD Program in Microbiology and Molecular Genetics, Rutgers, The State University of New Jersey, New Brunswick, NJ  
<sup>2</sup>Department of Molecular Biology and Biochemistry, Rutgers The State University of New Jersey, New Brunswick, NJ

#### **(A9) GENOMIC MARKERS OF RESPONSE TO NEOADJUVANT CARBOPLATIN AND LIPOSOMAL DOXORUBICIN TREATMENT IN TRIPLE NEGATIVE BREAST CANCER**

Xiaoju Hu, Nancy Chan, Gregory Riedlinger, Seema Husain, Deborah Toppmeyer, Subhajyoti De, Shridar Ganesan  
Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

#### **(A10) IDENTIFYING DNA SEQUENCE MOTIFS DISTINCTIVE TO COMMON FRAGILE SITES: A COMPREHENSIVE SURVEY OF REPETITIVE PATTERNS AND THEIR RELATIONSHIP TO GENOMIC INSTABILITY**

Nahed Jalloul, Hossein Khiabani, Advaita Madireddy  
Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

# PROGRAM SCHEDULE

## Focus Session A – Multi-Purpose Room A

### Cancer Pharmacology

3:00 P.M. – 4:00 P.M.

*Co-Chairs:* **Daniel Herranz Benito, PhD**, Assistant Professor of Pharmacology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ  
**Pranela Rameshwar, PhD**, Professor of Medicine, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

#### **(A11) COMBINATORIAL TREATMENT WITH INHIBITORS AGAINST GLUTAMATERGIC SIGNALING AND IMMUNE-CHECKPOINT, RESULTED IN A REDUCTION OF TUMOR GROWTH, AND IMPROVED SURVIVAL IN A SPONTANEOUS MELANOMA MOUSE MODEL**

Kevinn Eddy<sup>1,2</sup>, Christina Marinaro<sup>1</sup>, Maryam Rasheed<sup>1</sup>, Mohamad N. Eddin<sup>1</sup>, Joseph Campagnolo<sup>1</sup>, Raj Shah<sup>1</sup>, Kajal Gupta<sup>5</sup>, Anna Chaly<sup>6</sup>, Katie B. Freeman<sup>6</sup>, Jeffrey C. Pelletier<sup>6</sup>, Allen B. Reitz<sup>6</sup>, Andrew Zloza<sup>5</sup>, Suzie Chen<sup>1,2,3,4</sup>  
<sup>1</sup>Susan Lehman Cullman Laboratory for Cancer Research, Rutgers, The State University of New Jersey, Piscataway, NJ  
<sup>2</sup>Graduate Program in Cellular and Molecular Pharmacology, Rutgers, The State University of New Jersey, Piscataway, NJ  
<sup>3</sup>Rutgers Cancer Institute of New Jersey, New Brunswick, NJ  
<sup>4</sup>Environmental & Occupational Health Sciences Institute, Rutgers, The State University of New Jersey, Piscataway, NJ  
<sup>5</sup>Rush University Medical Center, Chicago, IL  
<sup>6</sup>Fox Chase Chemical Diversity Center, Inc., King of Prussia, PA

#### **(A12) CAFFEINE PREVENTS CISPLATIN-INDUCED COGNITIVE DYSFUNCTION IN MICE**

Alfredo A. Oliveros<sup>1,2</sup>, Marwan Mostafa<sup>1</sup>, Ivan Loncar<sup>1</sup>, Ki-Hyun Yoo<sup>1,2</sup>, Ana M. Corujo<sup>1</sup>, Mi-Hyeon Jang<sup>1,2</sup>  
<sup>1</sup>Neurosurgery Department, Rutgers Robert Wood Johnson Medical School, Piscataway, NJ  
<sup>2</sup>Department of Neurological Surgery, Mayo Clinic College of Medicine, Rochester MN

#### **(A13) DEVELOPMENT OF A BISPECIFIC ANTIBODY FOR NATURAL KILLER CELL-BASED IMMUNOTHERAPY OF HER2+ OVARIAN CANCER**

Shahryar K. Nikkhai, Arash Hatefi  
Department of Pharmaceutics, Rutgers, The State University of New Jersey, Piscataway, NJ

#### **(A14) MTOR REGULATES ARID1A DEGRADATION AND CHROMATIN REMODELING IN TUMORIGENESIS AND ANTICANCER THERAPY**

Tinghan Zhao<sup>1</sup>, Shanshan Zhang<sup>1</sup>, Shuyang Liu<sup>1,2</sup>, Jian Cao<sup>1,3</sup>, Stephen K. Burley<sup>1,4</sup>, X.F. Steven Zheng<sup>1,5</sup>  
<sup>1</sup>Rutgers Cancer Institute of New Jersey, New Brunswick, NJ  
<sup>2</sup>School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ  
<sup>3</sup>Department of Medicine, Rutgers, The State University of New Jersey, Piscataway, NJ  
<sup>4</sup>Institute for Quantitative Biomedicine, Rutgers, The State University of New Jersey, Piscataway, NJ  
<sup>5</sup>Department of Pharmacology, Rutgers, The State University of New Jersey, Piscataway, NJ

#### **(A15) SIGMA 1 RECEPTOR ANTAGONISTS AS THERAPEUTICS FOR CHEMOTHERAPY-INDUCED PAIN**

Youyi Peng<sup>1</sup> and William J. Welsh<sup>1,2</sup>  
<sup>1</sup>Rutgers Cancer Institute of New Jersey, New Brunswick, NJ  
<sup>2</sup>Rutgers Robert Wood Johnson Medical School, Piscataway, NJ

# PROGRAM SCHEDULE

## Focus Session B – Multi-Purpose Room B

### *Clinical Investigations and Precision Therapeutics*

1:00 P.M. – 2:00 P.M.

*Co-Chairs:* **Coral Omene, MD, PhD**, Assistant Professor of Medicine, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ  
**Prateek Gulhati, MD, PhD**, Assistant Professor of Medicine, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

#### **(B1) EXPLORING THE INTERPLAY OF GENOMIC REARRANGEMENTS, HOST FACTORS THAT IMPACT CANCER DISPARITIES, AND RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN BLACK WOMEN WITH TRIPLE NEGATIVE BREAST CANCER**

Coral Omene<sup>1</sup>, Gregory Riedlinger<sup>2</sup>, Yaqun Wang<sup>3</sup>, Ying Chen<sup>4</sup>, Adana A.M. Llanos<sup>5</sup>, Elisa V. Bandera<sup>1,3</sup>, Shridhar Ganesan<sup>1</sup>

<sup>1</sup>Division of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

<sup>2</sup>Division of Translational Pathology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

<sup>3</sup>Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

<sup>4</sup>Division of Medical Informatics, Department of Pathology & Laboratory Medicine, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

<sup>5</sup>Department of Epidemiology, Mailman School of Public Health and Columbia University Irving Medical Center, New York, NY

#### **(B2) THE LANDSCAPE OF GENETIC ALTERATIONS BASED ON TP53 STATUS IN PATIENTS WITH PANCREATIC ADENOCARCINOMA AND ITS PROGNOSTIC SIGNIFICANCE**

Jongmyung Kim, Huzaiifa Piperdi, Salma K. Jabbour, Matthew P. Deek

Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

#### **(B3) NEOADJUVANT CHEMOTHERAPY IN OVARIAN CANCER: RACIAL DISPARITIES IN USE AND SURVIVAL OUTCOMES**

Saber A. Amin<sup>1</sup>, Soko Setoguchi<sup>2</sup>, Jaya M. Satagopan<sup>3</sup>, Alexandre Buckley de Meritens<sup>4</sup>, Elisa V. Bandera<sup>1</sup>

<sup>1</sup>Cancer Epidemiology and Health Outcomes, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

<sup>2</sup>Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ

<sup>3</sup>Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Piscataway, NJ

<sup>4</sup>Department of OB/GYN and Reproductive Sciences, Division of Gynecologic Oncology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ

#### **(B4) PATHOLOGIC GLEASON GRADE GROUP 1 PROSTATE CANCER IN BLACK MEN – IMPLICATIONS FOR RENAMING IT “NOT CANCER” IN HIGH-RISK POPULATIONS**

Courtney Berg, Amjad Alwaal, Robert Weiss, Evan Kovac

Department of Surgery, Division of Urology, Rutgers New Jersey Medical School, Newark, NJ

Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

#### **(B5) ASSESSING PRELIMINARY OUTCOMES OF AN ONLINE RESISTANCE EXERCISE PROGRAM AMONG RACIALLY DIVERSE BREAST CANCER SURVIVORS IN NEW JERSEY**

Bianca Anuforo<sup>1</sup>, Shawna V. Hudson<sup>2</sup>, Sharon L. Manne<sup>1</sup>, Angela J. Fong<sup>1</sup>

<sup>1</sup>Section of Behavioral Sciences, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

<sup>2</sup>Department of Family Medicine and Community Health, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

# PROGRAM SCHEDULE

## Focus Session B – Multi-Purpose Room B

### Cancer Prevention and Control

2:00 P.M. – 3:00 P.M.

**Co-Chairs:** **Bo (Bonnie) Qin, PhD**, Assistant Professor of Cancer Epidemiology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ  
**Nur Zeinomar, PhD, MPH**, Instructor of Medicine, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

#### **(B6) MULTILEVEL FACTORS FOR ADIPOSITY CHANGE IN A POPULATION-BASED PROSPECTIVE STUDY OF BLACK BREAST CANCER SURVIVORS**

Qin B<sup>1,2</sup>, Kim K<sup>2</sup>, Goldman N<sup>3</sup>, Rundle AG<sup>4</sup>, Chanumolu D<sup>1</sup>, Zeinomar N<sup>1,2</sup>, Xu B<sup>1</sup>, Pawlish KS<sup>5</sup>, Ambrosone CB<sup>6</sup>, Demissie K<sup>7</sup>, Hong CC<sup>6</sup>, Lovasi GS<sup>8</sup>, Bandera EV<sup>1,2</sup>

<sup>1</sup>Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

<sup>2</sup>Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ

<sup>3</sup>Princeton University, Princeton, NJ

<sup>4</sup>Columbia University, New York, NY

<sup>5</sup>New Jersey Department of Health, Trenton, NJ

<sup>6</sup>Roswell Park Comprehensive Cancer Center, Buffalo, NY

<sup>7</sup>SUNY Downstate Health Sciences University, Brooklyn, NY

<sup>8</sup>Drexel University, Philadelphia, PA

#### **(B7) HEAVY DRINKING IN CANCER PATIENTS AND SURVIVORS DURING THE COVID-19 PANDEMIC IN THE US**

Yen-Hong Kuo

Office of Research Administration, Hackensack Meridian Health, Neptune, NJ

#### **(B8) RACIAL DISPARITIES IN FEMALE BREAST CANCER SURVIVAL BY MOLECULAR SUBTYPE, AGE, GRADE, AND STAGE**

Muhammad Ahmed<sup>1</sup>, Lisa E. Paddock<sup>1,2</sup>, Gerald Harris<sup>1</sup>, Karen Pawlish<sup>2</sup>, Susan German<sup>1</sup>, Pamela Agovino<sup>2</sup>, Antoinette M. Stroup<sup>1,2</sup>

<sup>1</sup>Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

<sup>2</sup>New Jersey Department of Health, Trenton, NJ

#### **(B9) HPV VACCINE HESITANCY AND INFORMATION NEEDS IN LOW-UPTAKE COMMUNITIES**

Racquel E. Kohler<sup>1,2</sup>, Rachel Wagner<sup>1</sup>, Katherine Careaga<sup>1</sup>, Jacqueline Vega<sup>1</sup>, Rula Btoush<sup>3</sup>, Kathryn Greene<sup>4</sup>, Leslie M. Kantor<sup>2</sup>

<sup>1</sup>Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

<sup>2</sup>Rutgers School of Public Health, Rutgers, The State University of New Jersey, Piscataway, NJ

<sup>3</sup>Rutgers School of Nursing, Rutgers, The State University of New Jersey, New Brunswick, NJ

<sup>4</sup>Rutgers School of Communication and Information, Rutgers, The State University of New Jersey, New Brunswick, NJ

#### **(B10) PRIMARY CARE PHYSICIAN BELIEFS AND PRACTICES REGARDING LUNG CANCER SCREENING**

Steinberg MB, Ramdat C, Jordan HM, Young W, Garthe N, Kota KJ, Musanti R, Kinney AY

Rutgers Center for Tobacco Studies, New Brunswick, NJ

Rutgers Cancer Institute of New Jersey, New Brunswick, NJ